Related Experiment Video
Updated: Jun 20, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients
Hiroyuki Hayashida1, Naoki Haruyama1, Akiko Fukui1
1Division of Nephrology, Department of Internal Medicine, NHO Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Insights
High B-type natriuretic peptide (BNP) levels in chronic kidney disease (CKD) patients are linked to increased cardiovascular events and mortality. This association persists even when accounting for cardiac changes, highlighting BNP as a key risk indicator.
Area of Science:
- Nephrology
- Cardiology
- Biomarkers
Background:
- The prognostic value of B-type natriuretic peptide (BNP) in chronic kidney disease (CKD) patients is not fully understood.
- Cardiovascular (CV) disease is a leading cause of mortality in CKD patients.
Purpose of the Study:
- To investigate the association between BNP levels and CV events or mortality in CKD patients.
- To determine if BNP predicts CV outcomes independently of cardiac alterations.
Main Methods:
- Prospective study of 1078 CKD patients.
- Patients categorized into low (<40 pg/mL), middle (40-100 pg/mL), and high (>100 pg/mL) BNP groups.
- Primary outcome: fatal/nonfatal CV events. Alternative outcome: composite of CV events or non-CV deaths. Cox regression analysis adjusted for covariates.
Main Results:
- High BNP levels (HR 1.72; 95% CI 1.06-2.79) were independently associated with CV events compared to low BNP levels.
- Similar associations observed for the composite outcome (HR 1.54; 95% CI 1.04-2.27).
- These associations remained significant after adjusting for cardiac parameters.
Conclusions:
- Elevated BNP concentrations are an independent predictor of cardiovascular events and mortality in CKD patients.
- BNP provides prognostic information beyond traditional cardiac assessments in this population.
- BNP may serve as a valuable biomarker for risk stratification in CKD.
Abstract:
The association between B-type natriuretic peptide (BNP) and cardiovascular (CV) events and mortality has not been well characterized in patients with chronic kidney disease (CKD). We prospectively investigated whether BNP was associated with CV events or mortality beyond cardiac alterations in 1078 patients with CKD. Participants were divided into the following 3 groups according to circulating BNP concentration: < 40 pg/mL, low; 40-100 pg/mL, middle; and > 100 pg/mL, high. Primary outcome was fatal or nonfatal CV events, and alternative outcome was a composite of fatal or nonfatal CV events, or non-CV deaths. During a median follow-up of 2.6 years, CV and composite events occurred in 158 and 248 participants, respectively. Cox analyses after adjustment for covariates, including cardiac parameters, showed that the hazard ratios (HRs) (95% confidence intervals [CIs]) for CV events of middle and high groups were 1.00 (0.63, 1.58) and 1.72 (1.06, 2.79), respectively, compared with low group. Additionally, similar results were obtained for composite events; the HRs (95% CIs) of middle and high groups were 1.10 (0.77, 1.57) and 1.54 (1.04, 2.27), respectively, compared with low group. Thus, in CKD, high BNP concentrations were independently associated with CV events and mortality, independent of cardiac alterations.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
Nephrons
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...

